ONCOLOGY PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | +9,900.00% |
|
+4,999,900.00% | -50.00% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2003 | 3.28M 4.47M | Sales 2004 | 1.18M 1.61M | Capitalization | 3.87K 5.26K |
|---|---|---|---|---|---|
| Net income 2003 | -1M -1.36M | Net income 2004 | -1M -1.36M | EV / Sales 2003 | - |
| Net cash position 2003 | 1.35M 1.83M | Net Debt 2004 | 17K 23.14K | EV / Sales 2004 | - |
| P/E ratio 2003 * |
-
| P/E ratio 2004 |
-
| Employees | - |
| Yield 2003 * |
-
| Yield 2004 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +9,900.00% | ||
| 6 months | -90.00% | ||
| Current year | -50.00% |
1 week
0.00
0.05
1 month
0.000.06
Current year
0.000.18
1 year
0.001.05
3 years
0.0038.25
5 years
0.0050.00
10 years
0.0039 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
George Malesek
CEO | Chief Executive Officer | - | - |
James B. Smith
DFI | Director of Finance/CFO | - | 21-01-27 |
Charles Wagner
CHM | Chairman | - | 14-09-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stefan Gruenwald
BRD | Director/Board Member | - | 19-10-07 |
Charles Wagner
CHM | Chairman | - | 14-09-29 |
Carlos Barnett
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 0.0001 | +9,900.00% | 990 |
| 24-05-14 | 0.000001 | -99.00% | 390 |
| 24-05-13 | 0.0001 | +9,900.00% | 3,407 |
| 24-05-09 | 0.000001 | 0.00% | 808 |
| 24-05-08 | 0.000001 | -99.00% | 200 |
Delayed Quote OTC Markets, May 15, 2024 at 11:30 am
More quotes
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâs research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâs NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 3.87K | |
| +32.98% | 709B | |
| +30.77% | 595B | |
| -1.87% | 367B | |
| +20.21% | 334B | |
| +5.89% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.03% | 171B |
- Stock Market
- Equities
- ONPH Stock
